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A B S T R A C TObjectives: Hemophilia is an X-chromosome–linked disorder associ-
ated with recurrent bleeding into muscles and joints, leading to pain
and limitations in physical function that may diminish quality of life.
The Canadian Hemophilia Outcomes–Kids Life Assessment Tool (CHO-
KLAT) is a disease-specific measure of quality of life that was recently
revised to facilitate cross-cultural adaptation. This study assessed the
validity and reliability of version 2.0 of the CHO-KLAT (CHO-KLAT2.0).
Methods: Content validity was assessed via detailed cognitive debrief-
ing to confirm that Canadian boys understood the CHO-KLAT2.0. The
measurement properties of the CHO-KLAT2.0 were assessed in compar-
ison to those of the PedsQL, the Haemo-QoL, and two global ratings.
Most children completed the CHO-KLAT2.0 a second time to assess test-
retest reliability. Results: Cognitive debriefing was completed with 12
boys (age 8.6–17.8 years) and 9 of their parents and resulted in no
substantive changes. Sixty boys (mean age 11.8 years) participated in
the validation phase, which showed a mean CHO-KLAT2.0 score ofsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.02.004
laurentian.ca.
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a P3E 2C6.75.4  12.0, strong correlations with the PedsQL (r ¼ 0.62, Po 0.001)
and Haemo-QoL (r ¼ 0.64, Po 0.001), and moderate correlations with
global ratings of hemophilia bother (r ¼ 0.39, P ¼ 0.002) and health
(r ¼ 0.47, P ¼ 0.0002). Test-retest concordance was better among
parents (0.79) than among boys (0.63). Conclusions: This study estab-
lishes the measurement properties of the CHO-KLAT2.0. The sum-
mary scores are very similar to those from the original
development study, and thus, these have not been affected by the
revisions. These results provide reference standards for comparing
data from other countries to the Canadian experience and to
estimate sample sizes for future clinical trials.
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Hemophilia is a congenital, X-chromosome–linked recessive
bleeding disorder that results in low levels of either factor VIII
(hemophilia A) or factor IX (hemophilia B) [1]. The incidence of
hemophilia A is approximately 1 in 5,000 male live births;
hemophilia B is less common, with an incidence of approxi-
mately 1 in 30,000 male live births [1]. Boys with severe hemo-
philia A and B experience recurrent bleeding into joints, muscles,
and soft tissues [1]. Repeated bleeds can cause permanent
damage to joints and soft tissues, with associated pain and
limitations in physical function, resulting in diminished quality
of life (QOL).
In Canada, boys with hemophilia are treated by intravenous
infusions of factor concentrates. For those individuals with mild
disease, bleeding is usually associated with trauma and thus
treatment (referred to as ‘‘on-demand’’ therapy) is given only
following bleeding or in preparation for invasive procedures,
such as surgery. Individuals with severe hemophilia typicallyexperience unprovoked bleeding and are increasingly treated
with prophylaxis, where factor replacement therapy is given on
a regularly scheduled basis (generally two or three times per
week) to prevent significant bleeding and consequent arthrop-
athy [1]. Some aspects of treatment, for example, the need for
intravenous infusions, may also have a negative impact on QOL.
Thus, QOL is an important outcome measure for studies of
hemophilia [2–4].
QOL has been defined by the World Health Organization as the
net consequence of life characteristics on a ‘‘person’s perception
of their position in life, in the context of the culture and value
systems in which they live, and in relation to their goals,
expectations, standards, and concerns’’ [5]. Health-related quality
of life (HRQOL) often refers to the specific impact a disease or
illness may have on the overall QOL [6] and was introduced into
medical care because of the concern that the global concept of
QOL may not be affected by health care interventions [7]. In many
instances, however, the terms QOL and HRQOL are used inter-
changeably [8]. The constructs of QOL and HRQOL are subjective,Society for Pharmacoeconomics and Outcomes Research (ISPOR).
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dreams, and ambitions [6].
Canadian Hemophilia Outcomes–Kids Life Assessment Tool
Development
The Canadian Hemophilia Outcomes–Kids Life Assessment Tool
(CHO-KLAT) was developed to address the need for a disease-
specific measure [9]. CHO-KLAT’s validity was confirmed by a
correlation of 0.59 (P o 0.001) with the PedsQL [10]. The initial
version of the CHO-KLAT, tested on 52 boys with hemophilia (31%
moderate and 69% severe), had a mean score of 74.6  14.2 (range
¼ 33.9–97.2) [10]. By comparison, the mean PedsQL score was
84.0  16.2 (range ¼ 5.4–100) on the same clinical cohort, and the
mean Haemo-QoL score was 78.2  15.3 (range ¼ 17.9–99.3). A
ceiling effect was observed in four boys, but it occurred only with
the generic measure [10].
In 2008, we began a detailed process of linguistic translation
and cognitive debriefing to develop versions of the CHO-KLAT for
five European countries (France, Germany, The Netherlands,
Spain, and the United Kingdom). During this process, we identi-
fied that one of the response sets used in the original CHO-KLAT
(the seven-point Likert-type responses ranging from strongly
disagree to strongly agree) was not well understood by children in
Europe. However, the main response set (that ranged from never
to always) was well understood. Thus, our solution was to use the
main response set for all questions. Eleven of the 35 items
underwent changes in the question stem to accommodate the
change in response options. In addition, some minor wording
changes had occurred as part of the European cognitive debrief-
ing process and were incorporated. The revised tool is referred to
as the CH0-KLAT (version 2.0) (CH0-KLAT2.0) [11].
Purpose
The purpose of this study was to establish the validity and
reliability of the CHO-KLAT2.0. In addition, this study compared
the CHO-KLAT2.0 scores to those found in the original CHO-KLAT
validation study [10]. Finally, this report provides estimates of the
mean scores and SDs for use in sample size calculations for
future studies.Methods
Sample
This study included boys between the ages of 6 and 17 years who
were recruited from the Comprehensive Care Hemophilia Clinic
at The Hospital for Sick Children, Toronto. They were approached
in clinic or via invitations sent through the mail. Brief chart
reviews were conducted on each participant to record baseline
plasma levels of circulating clotting factor, identify their current
treatment protocol, and record the extent of joint damage. This
study had two main phases: a) cognitive debriefing and b) validity
and reliability. Participants were recruited separately for
each phase.
Data Collection for Cognitive Debriefing
This study began by confirming that Canadian boys understood
the CHO-KLAT2.0. This was assessed through a detailed cognitive
debriefing process, similar to that used in the initial CHO-KLAT
development study [9] and the recent European cross-cultural
adaptation study using the methodology as described by Price
et al. [12]. This involved detailed individual interviews with 5 to
10 boys with hemophilia and a separate interview with one
parent of each boy. These interviews were conducted in thehematology outpatient clinic at The Hospital for Sick Children in
Toronto. The cognitive debriefing results were entered into an
Excel spreadsheet and analyzed in an iterative process.
After each series of two to three boys and their parents had
completed the cognitive debriefing process, the cumulative
results were used to catalog problems. The research team then
met to discuss any problems and revise questions, if necessary, to
improve the consistency and accuracy of question comprehen-
sion. This process continued until all items were consistently and
accurately interpreted by participants.
Data Collection for Validity and Reliability
The second phase of this study evaluated the measurement
properties of CHO-KLAT2.0 via mail-administered surveys. Boys
and their parents were requested to complete a survey package
containing a consent/assent (as required), a global health rating
form, the CHO-KLAT2.0, the PedsQL [13–15], and the Haemo-QoL
[2,16]. Boys and parents were instructed to complete these self-
report surveys independently. Participants were requested to
complete packages twice, approximately 2 weeks apart, at home,
and return the survey in a prepaid envelope. The two packages
were mailed separately, with each participant’s time 2 packages
mailed when their time 1 package was returned. Phone calls were
made after the packages were sent to ensure that they were
received. Reminder phone calls were made by the team if the
packages were not completed in a timely fashion [17]. Demo-
graphic forms were completed by study staff and details con-
firmed with parents.
Analysis
Analysis of the data from this study was done by using Stata
version 11.0.
Analysis for Cognitive Debriefing
The cognitive debriefing data were reviewed to describe the
sample and determine the number of items with comments
and the number of revisions required.
Analysis for Validity and Reliability
The survey analysis began by describing the sample. Disease
severity was defined by baseline plasma levels of circulating
clotting factor (mild4 5%; moderate 1%–5%; and severeo1%)
[18]. We classified all survey participants on the basis of their
current treatment regime and recent bleeding history, because
these characteristics are expected to affect QOL outcomes. The
treatment protocol was either on-demand (i.e., treated only when
a bleed occurred) or on-prophylaxis (i.e., treated on a regular
basis to prevent bleeds). Recent episode(s) of bleeding were based
on self-report for the 2-week period preceding the completion of
the surveys, and were subdivided into no bleeds, recent bleed
(occurring between 24 hours and 2 weeks prior to the survey),
and current bleed (occurring in the 24-hour period prior to the
survey). This resulted in four possible groups. Details of the
groups are listed in Table 1 in the Results section.
Summary scores were calculated for each measure according
to the rules provided by the developers. Pearson’s correlations
were computed to establish the validity of the CHO-KLAT2.0
relative to the PedsQL. The original CHO-KLAT had a correlation
of 0.59 (P o 0.001) with the PedsQL [10]. Thus, a similar correla-
tion was expected in this study. Because the PedsQL was believed
to be a rough approximation of QOL in this population, we also
compared the CHO-KLAT2.0 to the Haemo-QoL (a disease-specific
measure) by using a Pearson’s correlation. In addition, we
compared the CHO-KLAT2.0 to a global rating of how much they
Table 1 – Group classification.
Criteria Group 1 Group 2 Group 3 Group 4
Sample size,
n (%)
22 (36.7) 24 (40.0) 10 (16.7) 4 (6.7)
Current
treatment
regime
On-demand Prophylaxis
(Z1 dose/wk)
Any treatment
Recent
episode(s) of
bleeding
0 self-reported bleeds in the 2-wk
period preceding survey completion
Z1 self-reported bleed in
the 24-ho to 2-wk period
preceding survey
completion
Z1 self-reported bleed
in the 0- to 24-ho
period preceding
survey completion
QOL
prediction
Best----------------------------------------Worst
QOL, quality of life.
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general health by using a Spearman’s correlation coefficient.
We then explored the distribution of scores according to our
clinical classification into four groups that were expected to
range from best QOL (group 1) to worst QOL (group 4). Note that
group 4 members were expected to have significantly lower
scores because they had a current bleed during the period of
self-report. We tested this hypothesis by using an analysis of
variance.
Once validity had been established, we assessed the reliability
of the CHO-KLAT2.0. Only those children who recorded their own
answers were included in the reliability analysis. The test-retest
reliability of scores was assessed, between time 1 (baseline) and
time 2 (follow-up), by using a random effects model intraclass
correlation coefficient (ICC) [19]. Only those children who were
clinically stable during this time period were included in the test-
retest analysis. The concordance of the CHO-KLAT2.0 between
child and parent respondents was assessed by using baseline
data, with a random effects ICC.Results
Results of Cognitive Debriefing
The cognitive debriefing process was completed with 12 boys and
9 of their parents (89% of whom were mothers). Their mean age
was 11.7  3.0 (range ¼ 8.6–17.8) years. Three boys had moderate
hemophilia, and nine boys had severe hemophilia. Ten were on
prophylaxis, and all 10 were on home treatment. The boys had
suggestions related to 24 items, and the parents had suggestions
related to 8 items. These suggestions varied across the partic-
ipants, with few consistent recommendations. After analysis andTable 2 – Child-reported baseline scores.
Child self-report scores
CHO-KLAT2.0 PedsQL Haemo-Q
n 60 60 60
Mean 75.4 80.9 75.6
SD 11.98 13.69 14.42
Minimum 47.8 45.7 22.9
Maximum 98.4 100.0 100.0
CHO-KLAT2.0, Canadian Hemophilia Outcomes–Kids Life Assessment Toodiscussion, minor changes were made to 3 items, which were
primarily changes to examples. No substantive changes were
required.Results of Validity and Reliability
A total of 61 boys and 60 of their parents participated in this
second part of the study, which evaluated the measurement
properties of the CHO-KLAT2.0. Because of data quality issues, the
data from one participant and parent pair were excluded from
the analysis. The mean age of the 60 boys analyzed in this study
was 11.8  3.5 (range ¼ 6.3–17.8) years.
In this sample, 13 boys had mild hemophilia and all were
receiving on-demand therapy, 16 had moderate disease of whom
10 were receiving on-demand therapy, and 31 had severe disease
of whom only 1 was receiving on-demand therapy with the
others receiving prophylaxis. In total, 40% of the study cohort
was receiving on-demand therapy and 60% was receiving pro-
phylaxis. These participants were classified into four groups as
shown in Table 1.
Half (51%) of the study cohort had no joint damage detected
by physiotherapy examination. The majority of those with joint
damage had one involved joint (29%), and all others had between
two and four joints involved. Most of the participants (75%)
completed the study a second time to assess reliability.
The child-reported QOL score distributions from baseline
(time 1) are presented in Table 2. Parents also provided data for
this study. These were provided predominantly by mothers (81%),
with the remainder being provided by fathers. Summary scores
reported by the parents are also presented in Table 2.
The validity of the CHO-KLAT2.0 was determined in compar-
ison to the PedsQL and Haemo-QoL, using child self-report
data from baseline. The Pearson’s correlation between theParent proxy-report scores
oL CHO-KLAT2.0 PedsQL Haemo-QoL
60 60 60
77.0 78.6 76.6
11.55 16.54 14.26
44.1 23.9 39.3
96.3 100.0 99.3
l (version 2.0); QOL, quality of life.
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Overall, how much are you bothered by your hemophilia?
Fig. 1 – CHO-KLAT2.0 by general bother rating (based on child
report). CHO-KLAT2.0, Canadian Hemophilia Outcomes–Kids
Life Assessment Tool (version 2.0).
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 8 3 7 – 8 4 1840CHO-KLAT2.0 and the PedsQL was 0.62 (Po 0.0001). The Pearson’s
correlation between the CHO-KLAT2.0 and the Haemo-QoL was
0.64 (P o 0.0001).
The degree of correlation between the CHO-KLAT2.0 and the
global rating of how much they were bothered by their hemo-
philia was 0.39 (P ¼ 0.002). The relationship between
CHO-KLAT2.0 scores and the degree of bother ratings is shown
in Figure 1. The Spearman’s correlations with the degree of
bother were 0.25 (P ¼ 0.058) for the PedsQL and 0.43 (P ¼
0.0006) for the Haemo-QoL. The Spearman’s correlation between
the CHO-KLAT2.0 and the global rating of health was 0.47 (P ¼
0.0002). The Spearman’s correlations with the global rating of
health were similar for the PedsQL (0.46, P ¼ 0.0003) and the
HaemoQoL (0.53, Po 0.0001).
The child-reported CHO-KLAT2.0 score distributions are shown
by group in Figure 2. The means  SDs were as follows: group 1,
79.6  8.13; group 2, 77.3  11.13; group 3, 69.2  12.61; and group 4,
56.3  12.59. We tested the significance of the relationship between
group classification and CHO-KLAT2.0 scores by using analysis of
variance. We found a statistically significant relationship (P ¼
0.0004), with 27% of the variance in scores being explained by the10
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Fig. 2 – CHO-KLAT2.0 scores by group (based on child report).
CHO-KLAT2.0, Canadian Hemophilia Outcomes–Kids Life
Assessment Tool (version 2.0).group classification. Exploratory t tests between groups showed
statistically significant differences (Pr 0.05) between each pair of
groups, with the exception of between groups 1 and 2.
Responsiveness to change was explored by comparing the
summary scores between those who reported a bleed during the
2-week period prior to completing the survey and those who had
not. The CHO-KLAT2.0 showed a 12.2-point difference between
those with and without a recent bleed (P ¼ 0.0002). Note that
while both the other QOL measures also detected differences
between those with and without a bleed, these differences were
smaller: the PedsQL difference was 8.0 (P ¼ 0.03) and the Haemo-
QoL difference was 9.6 (P ¼ 0.01).
Reliability
The ICC between time 1 and 2 was computed for 24 boys who had
indicated stable disease status between the two time points and
who recorded their own answers. On average, the first and
second assessments were completed 19 days apart (range ¼
3–37 days, median of 17.5 days). The test-retest reliability of the
CHO-KLAT2.0 was 0.63 based on two-way random effects absolute
agreement. The test-retest concordance for parent-proxy report
was analyzed on the basis of data from 26 parents whose first
and second assessments were completed an average of 22 days
apart (range 6–40 days, median of 21 days). Parents’ test-retest
reliability was better than their children’s at 0.79. The child-
parent concordance for the 43 boys, for whom we had independ-
ent child and parent report at baseline, was 0.65 for the CHO-
KLAT2.0.Discussion
The QOL of boys with hemophilia is expected to vary dependent
on the severity of the condition and the clinical management.
Thus, it is important to take these parameters into account when
comparing results to other populations. The participants
included in this study were typical of the clinical context of
hemophilia care in Canada, in which a high proportion of boys
with severe hemophilia are on long-term prophylaxis. Therefore,
we expect the results to be robust and generalizable to other
countries with a similar treatment pattern. It is also important to
recognize that the use of long-term prophylaxis essentially
renders boys with severe hemophilia to a clinical phenotype that
is more commonly seen among those with mild/moderate hemo-
philia (e.g., a low incidence of unprovoked bleeding into muscles
and joints).
The fact that the cognitive debriefing process did not identify
any significant changes confirmed the face validity of the
CHO-KLAT2.0. Confirmation of face validity was an essential
precursor before assessing construct validity and test-retest
reliability.
The assessment of validity indicates that the CHO-KLAT2.0 is
clearly able to distinguish between those who are very much
bothered by their hemophilia and those who are not, as is shown
in Figure 1. It is also able to distinguish between clinically
different groups, based on current treatment regimens and
recent bleeding history, as is shown in Figure 2. The responsive-
ness exploration shows that the CHO-KLAT2.0 is also able to
distinguish between those with a recent self-reported bleed and
those without. It is important to recognize that the sample size in
the group with a current bleed (group 4) was very small (n ¼ 4).
The combined results of those with recent and current bleeds,
however, suggest that bleeding has a significant impact on QOL.
The reliability results indicate more variability in self-reported
scores than was observed in the initial development study [10].
The child self-report ICCs remain, however, within the
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 8 3 7 – 8 4 1 841‘‘substantial’’ range of agreement [20]. These reliability scores
were based on data that were collected over a longer time span
than is typical for test-retest studies, and may explain, at least in
part, the difference in concordance values between the initial
CHO-KLAT study and this study.Conclusions
The results of this study establish the measurement properties of
the new version of the CHO-KLAT. The mean summary score of
75.4 is very similar to the mean from the original CHO-KLAT
development study (74.6) [10]. The current study sample included
13 boys with mild disease. When they are excluded, the mean is
almost identical (74.5) to the mean from the original development
study. Thus, the changes in the response options for 11 items
have not affected the summary score distribution. The test-retest
reliability of the CHO-KLAT2.0 based on child self-report scores
was lower than expected; however, it remained acceptable.
The results provide means and SDs by groups based on current
treatment regime and recent bleeding patterns to aid in sample
size calculations in future trials. These values may also provide a
reference standard for comparing data from other countries to the
Canadian standards. The data from countries in which prophy-
laxis is less common are expected to show much lower CHO-
KLAT2.0 scores, particularly among those with severe hemophilia.
This report adds to the literature by identifying that 27% of
the variability in QOL scores was predicted by the classification
system used in this report. This finding suggests that other
factors, beyond treatment and bleeding patterns, have an
important impact on the QOL of boys with hemophilia in the
Canadian context. Future research should explore the role of
non–hemophilia-related factors on QOL. These studies should
include adequate numbers of cases representing the full
spectrum of hemophilia in terms of severity (mild, moderate,
severe), treatment regimens (on-demand or episodic treat-
ment vs. long-term prophylaxis), and clinical bleeding pat-
terns (frequent vs. infrequent bleeders) to provide the
necessary discriminatory power and thus improve our under-
standing of the multiple factors contributing to QOL in boys
with hemophilia.Acknowledgments
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